z-logo
open-access-imgOpen Access
Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”
Author(s) -
Muggia Franco
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13572
Subject(s) - carboplatin , paclitaxel , medicine , ovarian cancer , oncology , schedule , chemotherapy , cancer , cisplatin , computer science , operating system
First‐line ovarian cancer platinum doublet is paclitaxel‐carboplatin. Superiority of weekly paclitaxel schedules has not been confirmed; however, a novel schedule with both drugs given weekly (days 1, 8, 15) followed by a 2‐week break may be advantageous to some.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here